Table of Content

Open Access iconOpen Access

ARTICLE

Utility of the Aortic-Lesion-AttenuationDifference (ALAD) and Peak Early-Phase Enhancement Ratio (PEER) to differentiate benign from malignant renal masses

Amanda E. Kahn1, Steven J. Lomax1, Essa M. Bajalia1, Colleen T. Ball2, David D. Thiel1

1 Department of Urology, Mayo Clinic, Jacksonville, Florida, USA
2 Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, Florida
Address correspondence to Dr. David D. Thiel, Department of Urology, Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224 USA

Canadian Journal of Urology 2020, 27(4), 10278-10284.

Abstract

Introduction: To evaluate the utility of the Aorta-Lesion-Attenuation-Difference (ALAD) and Peak Early-phase Enhancement Ratio (PEER) on contrast-enhanced computed tomography (CT) to differentiate between the appearances of chromophobe renal cell carcinoma, clear cell renal cell carcinoma, and oncocytoma.
Materials and methods: ALAD and PEER values were retrospectively measured by a reviewer from 119 patients with surgically resected renal masses (chromophobe renal cell carcinoma n = 29, clear cell renal cell carcinoma n = 28, and oncocytoma n = 62). The ALAD value is expressed as: ALAD = Hounsfield Units aorta – Hounsfield Units mass. PEER is expressed as (Hounsfield Units contrast tumor - Hounsfield Units non-contrast tumor):(Hounsfield Units contrast cortex - Hounsfield Units non-contrast cortex).
Results: The ALAD median was 27.6 for oncocytomas, 68.5 for chromophobe renal cell carcinoma, and 55.4 for clear cell renal cell carcinoma. A significant difference between ALAD values of oncocytoma and chromophobe renal cell carcinoma was observed in the nephrographic (area under the ROC curve 0.92) and excretory phases (area under the ROC curve 0.95). The PEER median was 0.74 for oncocytomas and 0.37 for chromophobe renal cell carcinoma. The PEER values significantly differed while comparing oncocytomas and chromophobe renal cell carcinoma in the nephrographic and excretory phases.
Conclusions: Preoperative contrast-enhanced CT ALAD and PEER values both significantly differentiate between chromophobe renal cell carcinoma and oncocytoma. PEER may be more effective in contrast-enhanced CT scans lacking distinct phases.

Keywords

x-ray computed, benign, carcinoma, renal cell, chromophobe renal cell carcinoma, oncocytoma, tomography

Cite This Article

APA Style
Kahn, A.E., Lomax, S.J., Bajalia, E.M., Ball, C.T., Thiel, D.D. (2020). Utility of the Aortic-Lesion-AttenuationDifference (ALAD) and Peak Early-Phase Enhancement Ratio (PEER) to differentiate benign from malignant renal masses. Canadian Journal of Urology, 27(4), 10278–10284.
Vancouver Style
Kahn AE, Lomax SJ, Bajalia EM, Ball CT, Thiel DD. Utility of the Aortic-Lesion-AttenuationDifference (ALAD) and Peak Early-Phase Enhancement Ratio (PEER) to differentiate benign from malignant renal masses. Can J Urology. 2020;27(4):10278–10284.
IEEE Style
A.E. Kahn, S.J. Lomax, E.M. Bajalia, C.T. Ball, and D.D. Thiel, “Utility of the Aortic-Lesion-AttenuationDifference (ALAD) and Peak Early-Phase Enhancement Ratio (PEER) to differentiate benign from malignant renal masses,” Can. J. Urology, vol. 27, no. 4, pp. 10278–10284, 2020.



cc Copyright © 2020 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 264

    View

  • 237

    Download

  • 0

    Like

Share Link